Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma

瑞戈非尼 肝细胞癌 医学 索拉非尼 内科学 肿瘤科 肿瘤进展 比例危险模型 胃肠病学 癌症研究 癌症 结直肠癌
作者
Michael Teufel,Henrik Seidel,Karl Köchert,Gerold Meinhardt,Richard S. Finn,Josep M. Llovet,Jordi Bruix
出处
期刊:Gastroenterology [Elsevier BV]
卷期号:156 (6): 1731-1741 被引量:166
标识
DOI:10.1053/j.gastro.2019.01.261
摘要

In a phase 3 trial (RESORCE), regorafenib increased overall survival compared with placebo in patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. In an exploratory study, we analyzed plasma and tumor samples from study participants to identify genetic, microRNA (miRNA), and protein biomarkers associated with response to regorafenib.We obtained archived tumor tissues and baseline plasma samples from patients with HCC given regorafenib in the RESORCE trial. Baseline plasma samples from 499 patients were analyzed for expression of 294 proteins (DiscoveryMAP) and plasma samples from 349 patients were analyzed for levels of 750 miRNAs (miRCURY miRNA PCR). Tumor tissues from 7 responders and 10 patients who did not respond (progressors) were analyzed by next-generation sequencing (FoundationOne). Forty-six tumor tissues were analyzed for expression patterns of 770 genes involved in oncogenic and inflammatory pathways (PanCancer Immune Profiling). Associations between plasma levels of proteins and miRNAs and response to treatment (overall survival and time to progression) were evaluated using a Cox proportional hazards model.Decreased baseline plasma concentrations of 5 of 266 evaluable proteins (angiopoietin 1, cystatin B, the latency-associated peptide of transforming growth factor beta 1, oxidized low-density lipoprotein receptor 1, and C-C motif chemokine ligand 3; adjusted P ≤ .05) were significantly associated with increased overall survival time after regorafenib treatment. Levels of these 5 proteins, which have roles in inflammation and/or HCC pathogenesis, were not associated with survival independently of treatment. Only 20 of 499 patients had high levels and a reduced survival time. Plasma levels of α-fetoprotein and c-MET were associated with poor outcome (overall survival) independently of regorafenib treatment only. We identified 9 plasma miRNAs (MIR30A, MIR122, MIR125B, MIR200A, MIR374B, MIR15B, MIR107, MIR320, and MIR645) whose levels significantly associated with overall survival time with regorafenib (adjusted P ≤ .05). Functional analyses of these miRNAs indicated that their expression level associated with increased overall survival of patients with tumors of the Hoshida S3 subtype. Next-generation sequencing analyses of tumor tissues revealed 49 variants in 27 oncogenes or tumor suppressor genes. Mutations in CTNNB1 were detected in 3 of 10 progressors and VEGFA amplification in 1 of 7 responders.We identified expression patterns of plasma proteins and miRNAs that associated with increased overall survival times of patients with HCC following treatment with regorafenib in the RESORCE trial. Levels of these circulating biomarkers and genetic features of tumors might be used to identify patients with HCC most likely to respond to regorafenib. ClinicalTrials.gov number NCT01774344. NCBI GEO accession numbers: mRNA data (NanoString): GSE119220; miRNA data (Exiqon): GSE119221.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
眼睛大淇完成签到,获得积分10
1秒前
boom完成签到 ,获得积分10
3秒前
偶尔向上idiot完成签到 ,获得积分10
3秒前
11秒前
king完成签到 ,获得积分10
13秒前
14秒前
153266916完成签到 ,获得积分10
18秒前
文文发布了新的文献求助10
20秒前
韩梅完成签到 ,获得积分10
24秒前
活力尔柳完成签到 ,获得积分10
26秒前
27秒前
起名困难户完成签到,获得积分10
29秒前
u雨发布了新的文献求助10
33秒前
小周完成签到 ,获得积分10
34秒前
齐天小圣完成签到 ,获得积分10
41秒前
u雨完成签到,获得积分10
43秒前
困困困完成签到,获得积分10
45秒前
忧伤的白秋完成签到,获得积分10
45秒前
勤劳的乐蕊完成签到,获得积分10
48秒前
噜噜晓完成签到 ,获得积分10
50秒前
呆橘完成签到 ,获得积分10
51秒前
踏实谷蓝完成签到 ,获得积分10
53秒前
林韵悠扬完成签到 ,获得积分10
54秒前
土豆完成签到 ,获得积分10
55秒前
科研蛀虫完成签到 ,获得积分10
55秒前
黎咩e茹完成签到,获得积分10
55秒前
57秒前
苗条的奇异果完成签到,获得积分10
59秒前
细心又菡发布了新的文献求助10
1分钟前
腼腆的眼睛完成签到 ,获得积分10
1分钟前
沙莎完成签到 ,获得积分10
1分钟前
CodeCraft的应助被细心又菡采纳,获得10
1分钟前
meilirenshengzcs完成签到,获得积分10
1分钟前
石头完成签到 ,获得积分10
1分钟前
张长剑完成签到,获得积分10
1分钟前
chaosyw完成签到,获得积分10
1分钟前
Lucas的应助被张长剑采纳,获得10
1分钟前
黄锐完成签到 ,获得积分10
1分钟前
yeeja完成签到 ,获得积分10
1分钟前
冷静青枫完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012